Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche

Salvatore Condello, Livia Sima, Cristina Ivan, Horacio Cardenas, Gary Schiltz, Rama K. Mishra, Daniela Matei

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cancer progression and recurrence are linked to a rare population of cancer stem cells (CSC). Here, we hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase (TG2) in ovarian CSC. Complexes formed by TG2, fibronectin (FN), and integrin b1 were enriched in ovarian CSC and detectable in tumors. A function-inhibiting antibody against the TG2 FN-binding domain suppressed complex formation, CSC proliferation as spheroids, tumor-initiating capacity, and stemness-associated Wnt/b-catenin signaling. Disruption of the interaction between TG2 and FN also blocked spheroid formation and the response to Wnt ligands. TG2 and the Wnt receptor Frizzled 7 (Fzd7) form a complex in cancer cells and tumors, leading to Wnt pathway activation. Protein docking and peptide inhibition demonstrate that the interaction between TG2 and Fzd7 overlaps with the FN-binding domain of TG2. These results support a new function of TG2 in ovarian CSC, linked to spheroid proliferation and tumor-initiating capacity and mediated through direct interactions with Fzd7. We propose this complex as a new stem cell target. Significance: These findings reveal a new mechanism by which ovarian CSCs interact with the tumor microenvironment, promoting cell proliferation and tumor initiation.

Original languageEnglish (US)
Pages (from-to)2990-3001
Number of pages12
JournalCancer Research
Volume78
Issue number11
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Stem Cell Niche
Neoplastic Stem Cells
Ovarian Neoplasms
Fibronectins
Neoplasms
Cell Proliferation
Wnt Receptors
Catenins
Wnt Signaling Pathway
Tumor Microenvironment
Integrins
Extracellular Matrix
Proteins
Stem Cells
Ligands
Recurrence
Peptides
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche. / Condello, Salvatore; Sima, Livia; Ivan, Cristina; Cardenas, Horacio; Schiltz, Gary; Mishra, Rama K.; Matei, Daniela.

In: Cancer Research, Vol. 78, No. 11, 01.06.2018, p. 2990-3001.

Research output: Contribution to journalArticle

Condello, Salvatore ; Sima, Livia ; Ivan, Cristina ; Cardenas, Horacio ; Schiltz, Gary ; Mishra, Rama K. ; Matei, Daniela. / Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche. In: Cancer Research. 2018 ; Vol. 78, No. 11. pp. 2990-3001.
@article{7a5243085fc34bba9289a41ad444bd64,
title = "Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche",
abstract = "Cancer progression and recurrence are linked to a rare population of cancer stem cells (CSC). Here, we hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase (TG2) in ovarian CSC. Complexes formed by TG2, fibronectin (FN), and integrin b1 were enriched in ovarian CSC and detectable in tumors. A function-inhibiting antibody against the TG2 FN-binding domain suppressed complex formation, CSC proliferation as spheroids, tumor-initiating capacity, and stemness-associated Wnt/b-catenin signaling. Disruption of the interaction between TG2 and FN also blocked spheroid formation and the response to Wnt ligands. TG2 and the Wnt receptor Frizzled 7 (Fzd7) form a complex in cancer cells and tumors, leading to Wnt pathway activation. Protein docking and peptide inhibition demonstrate that the interaction between TG2 and Fzd7 overlaps with the FN-binding domain of TG2. These results support a new function of TG2 in ovarian CSC, linked to spheroid proliferation and tumor-initiating capacity and mediated through direct interactions with Fzd7. We propose this complex as a new stem cell target. Significance: These findings reveal a new mechanism by which ovarian CSCs interact with the tumor microenvironment, promoting cell proliferation and tumor initiation.",
author = "Salvatore Condello and Livia Sima and Cristina Ivan and Horacio Cardenas and Gary Schiltz and Mishra, {Rama K.} and Daniela Matei",
year = "2018",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-17-2319",
language = "English (US)",
volume = "78",
pages = "2990--3001",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche

AU - Condello, Salvatore

AU - Sima, Livia

AU - Ivan, Cristina

AU - Cardenas, Horacio

AU - Schiltz, Gary

AU - Mishra, Rama K.

AU - Matei, Daniela

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Cancer progression and recurrence are linked to a rare population of cancer stem cells (CSC). Here, we hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase (TG2) in ovarian CSC. Complexes formed by TG2, fibronectin (FN), and integrin b1 were enriched in ovarian CSC and detectable in tumors. A function-inhibiting antibody against the TG2 FN-binding domain suppressed complex formation, CSC proliferation as spheroids, tumor-initiating capacity, and stemness-associated Wnt/b-catenin signaling. Disruption of the interaction between TG2 and FN also blocked spheroid formation and the response to Wnt ligands. TG2 and the Wnt receptor Frizzled 7 (Fzd7) form a complex in cancer cells and tumors, leading to Wnt pathway activation. Protein docking and peptide inhibition demonstrate that the interaction between TG2 and Fzd7 overlaps with the FN-binding domain of TG2. These results support a new function of TG2 in ovarian CSC, linked to spheroid proliferation and tumor-initiating capacity and mediated through direct interactions with Fzd7. We propose this complex as a new stem cell target. Significance: These findings reveal a new mechanism by which ovarian CSCs interact with the tumor microenvironment, promoting cell proliferation and tumor initiation.

AB - Cancer progression and recurrence are linked to a rare population of cancer stem cells (CSC). Here, we hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase (TG2) in ovarian CSC. Complexes formed by TG2, fibronectin (FN), and integrin b1 were enriched in ovarian CSC and detectable in tumors. A function-inhibiting antibody against the TG2 FN-binding domain suppressed complex formation, CSC proliferation as spheroids, tumor-initiating capacity, and stemness-associated Wnt/b-catenin signaling. Disruption of the interaction between TG2 and FN also blocked spheroid formation and the response to Wnt ligands. TG2 and the Wnt receptor Frizzled 7 (Fzd7) form a complex in cancer cells and tumors, leading to Wnt pathway activation. Protein docking and peptide inhibition demonstrate that the interaction between TG2 and Fzd7 overlaps with the FN-binding domain of TG2. These results support a new function of TG2 in ovarian CSC, linked to spheroid proliferation and tumor-initiating capacity and mediated through direct interactions with Fzd7. We propose this complex as a new stem cell target. Significance: These findings reveal a new mechanism by which ovarian CSCs interact with the tumor microenvironment, promoting cell proliferation and tumor initiation.

UR - http://www.scopus.com/inward/record.url?scp=85048049463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048049463&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-2319

DO - 10.1158/0008-5472.CAN-17-2319

M3 - Article

C2 - 29510995

AN - SCOPUS:85048049463

VL - 78

SP - 2990

EP - 3001

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -